Zosano Pharma Corporation is a commercially focused biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary intracutaneous microneedle patch technology. Zosano submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its lead clinical asset, Qtrypta*™ (M207) (zolmitriptan intracutaneous microneedle system) for the acute treatment of migraine, in Q4 2019.  Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies.

Learn More